Status: Recruiting
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
This is an open-label, single-arm, dose-escalation, multicenter phase I/II clinical trial. The primary endpoints of this study were to evaluated the safety, tolerability, pharmacokinetic profile and preliminary efficacy of HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy. The secondary endpoints of this study were to evaluated the efficacy HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy.
Participants needed: 120
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Hunan Province Tumor HospitalUpdated: May 30, 2024Locations: 1
Eligibility criteria
Sign written informed consent before implementing any trial-related procedures; [+8]
Subjects treated with CYP isozyme inducers or inhibitors (see Appendix 4 for det... [+7]